Zepbound for Sleep Apnea: Off-Label Evidence Summary
HealthRX.com
Zepbound is FDA-approved for moderate-to-severe sleep apnea
From the public record
Registered clinical studies of tirzepatide and sleep apnea
ClinicalTrials.gov lists 3 registered studies that name tirzepatide as an intervention and list sleep apnea as a condition, as of 2026-11-11. Of these, 0 are recruiting, 2 are completed and 2 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 3 |
| Recruiting now | 0 |
| Not yet recruiting | 1 |
| Completed | 2 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 (including phase 2/3) | 2 |
| Phase 2 (including phase 1/2) | 1 |
| Phase 1 | 0 |
How this was calculated
Searched ClinicalTrials.gov for studies naming the drug as an intervention with the stated filter, downloaded every matching record and counted by status and phase. Combined phases are counted under the higher phase.
Studies whose intervention field matches tirzepatide and that list sleep apnea as a condition, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported. The filter relies on how each study was registered.
From the public record
FDA label facts for tirzepatide
The FDA label read for tirzepatide (Zepbound, application NDA217806) was last revised on 2026-08-28. It carries a boxed warning headed "WARNING: RISK OF THYROID C-CELL TUMORS". Of the 4 population sections checked, 4 are present: pregnancy, lactation, pediatric use, geriatric use.
| Measure | Value | Note |
|---|---|---|
| Label revision date | 2026-08-28 | |
| Label read | Zepbound | NDA217806, brand-name application |
| Boxed warning | Yes | heading as printed: "WARNING: RISK OF THYROID C-CELL TUMORS" |
| Pregnancy section | Present | |
| Lactation section | Present | |
| Pediatric use section | Present | |
| Geriatric use section | Present |
How this was calculated
Selected the most recently revised prescription label for this single ingredient from an original manufacturer, preferring a brand-name application. Checked which sections exist and quoted headings and sentences exactly as printed.
One label: the newest prescription label for single-ingredient tirzepatide from an original manufacturer, matched to Zepbound
Read from one label. Labels for other brands, strengths or forms of the same ingredient can differ. A missing section heading does not mean there is no guidance. Read the full label before relying on it.
From the public record
Medicare Part D spending on tirzepatide
Medicare Part D spending on tirzepatide products was $6.34B in 2024 across 5,105,750 claims, compared with $2.36B in 2023 (+168.4%). Average spending per claim was $1,241, before rebates.
| Measure | Value | Note |
|---|---|---|
| Total spending, 2024 | $6.34B | |
| Total spending, 2023 | $2.36B | |
| Change in spending, 2023 to 2024 | +168.4% | |
| Claims (prescription fills), 2024 | 5,105,750 | |
| Average spending per claim, 2024 | $1,241 | |
| Mounjaro: spending, 2024 | $6.34B | 5,105,397 claims |
| Zepbound: spending, 2024 | $387,343 | 353 claims |
How this was calculated
Summed total spending and claims over every brand and generic row with this generic name in the CMS file, using the Overall manufacturer rows. Combination products excluded. Average per claim is spending divided by claims.
Every single-ingredient tirzepatide product in Part D (Mounjaro, Zepbound), 2024. Not limited to Zepbound.
Gross drug cost before manufacturer rebates, so net cost is lower. Part D excludes some uses by law (for example erectile dysfunction, weight loss and hair growth), so claims reflect covered uses only. Compounded products are not included.
At a glance
- FDA status / Approved for moderate-to-severe OSA in adults with obesity [1]
- Approval date for the OSA indication / 2024-12-20 [1]
- Approved OSA maintenance doses / 10 mg or 15 mg once weekly, after titration [1]
- Key trials / Two phase 3, double-blind, 52-week trials, tirzepatide vs placebo [2]
- AHI change, trial 1 (not on PAP) / -25.3 vs -5.3 events per hour; difference -20.0 [2]
- AHI change, trial 2 (on PAP) / -29.3 vs -5.5 events per hour; difference -23.8 [2]
- Mean baseline AHI / 51.5 events per hour (trial 1) and 49.5 (trial 2) [2]
Is Zepbound approved for sleep apnea?
Yes. The current Zepbound label (effective 2026-08-28) lists two indications, both used with a reduced-calorie diet and more physical activity: weight reduction and long-term weight maintenance in adults with obesity, or adults with overweight plus at least one weight-related condition; and treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity [1].
Two label points are worth knowing. The OSA indication is limited to adults with obesity, and the label's OSA maintenance doses are 10 mg or 15 mg once weekly, not the 5 mg dose that is also listed for weight reduction [1]. The label also states that coadministration with another tirzepatide-containing product or with any GLP-1 receptor agonist is not recommended [1].
What people on Reddit report
Accounts from people using Zepbound who tracked their sleep apnea. They include large improvements, partial improvement, and cases where CPAP was still needed. These are individual experiences, not trial results.
Had severe apnea with 52 events per hr, now down to 10 events per hour (mild) after losing almost 90 lbs.Read the source discussion
Yep, lost 64 lbs (219 to 155) and stopped using the CPAP, which I'd been using for almost 5 years and I desperately needed it. Now I don't snore and have no breathing issues at night.Read the source discussion
I can confirm that my sleep apnea has gotten significantly better with my use of Zepbound, but is not completely resolved.Read the source discussion
Anyway using Zepbound for 9 months has lessened my pressure needs with cpap. But has not eliminated the need for cpap in general. But I have severe apnea.Read the source discussion
Questions worth asking
Why weight and sleep apnea are connected
OSA is common. A literature-based analysis estimated that 936 million adults aged 30 to 69 have mild to severe OSA and 425 million have moderate to severe OSA worldwide; reliable prevalence data were available for 16 countries [3].
Weight and breathing during sleep move together over time. In a population-based cohort of 690 Wisconsin adults evaluated twice, four years apart, a 10% weight gain predicted about a 32% increase in AHI (95% CI 20% to 45%) and a 10% weight loss predicted a 26% decrease (95% CI 18% to 34%) [4]. A 10% increase in weight predicted a six-fold increase in the odds of developing moderate-to-severe sleep-disordered breathing (95% CI 2.2 to 17.0) [4]. This observational link provides context for the SURMOUNT-OSA trials [4][2].
What the two SURMOUNT-OSA trials found
SURMOUNT-OSA consisted of two phase 3, double-blind, placebo-controlled trials of 52 weeks. People not using positive airway pressure (PAP) at baseline were enrolled in trial 1, and people using PAP at baseline were enrolled in trial 2. Participants were assigned 1:1 to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo [2].
The primary endpoint was change in AHI. Mean baseline AHI was 51.5 events per hour in trial 1 and 49.5 in trial 2, with mean BMI of 39.1 and 38.7 [2]. At week 52, the mean AHI change in trial 1 was -25.3 events per hour with tirzepatide versus -5.3 with placebo, a difference of -20.0. In trial 2 the change was -29.3 versus -5.5, a difference of -23.8 [2].
Key secondary endpoints included percent change in AHI and body weight, hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein and systolic blood pressure [2]. A separate analysis of patient-reported outcomes reported significant improvements with tirzepatide in PROMIS sleep-related impairment and sleep disturbance scores, Functional Outcomes of Sleep Questionnaire activity-level scores, EQ-5D-5L scores and most domains of the SF-36, and trial 1 participants had a significant change in Epworth Sleepiness Scale scores [5].
One design detail is easy to miss. In trial 2, PAP was withdrawn before the polysomnography and patient-reported assessments [5]. The on-PAP results therefore describe breathing measured without PAP during the sleep study, not AHI while the device was running.
How does that compare with PAP?
In the SAVE trial of 2,717 adults with moderate-to-severe OSA and coronary or cerebrovascular disease, CPAP use averaging 3.3 hours per night lowered mean AHI from 29.0 to 3.7 events per hour [6]. SURMOUNT-OSA compared tirzepatide with placebo, not with PAP, so it did not test whether tirzepatide can replace PAP [2].
Whether treating OSA reduces cardiovascular events is a separate question from whether it lowers AHI. In SAVE, CPAP plus usual care did not reduce the primary cardiovascular composite compared with usual care alone (17.0% vs 15.4%; hazard ratio 1.10, 95% CI 0.91 to 1.32) [6]. For tirzepatide, a retrospective, propensity-matched cohort of people with both OSA and type 2 diabetes found lower rates of major adverse cardiovascular events over 18 months with tirzepatide than with liraglutide (hazard ratio 0.58) or semaglutide (hazard ratio 0.86) [7]. That is observational data, not a randomized cardiovascular outcome trial in OSA.
What the label says about dosing for OSA
The label says treatment starts at 2.5 mg once weekly for 4 weeks, and calls this an initiation dose that is not approved as a maintenance dose. It says that after 4 weeks the dose goes to 5 mg, and can then be raised in 2.5 mg steps after at least 4 weeks on the current dose. The label lists 10 mg or 15 mg once weekly as the recommended OSA maintenance doses, and 15 mg once weekly as the maximum for any indication [1].
For a missed dose, the label says to give it as soon as possible within 4 days (96 hours); if more than 4 days have passed, it says to skip the missed dose and resume the regular weekly schedule. The label also says the weekly injection day can be changed if the gap between two doses is at least 3 days (72 hours) [1].
What the label warns about
Zepbound carries a boxed warning for thyroid C-cell tumors seen in rats, with human relevance unknown, and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and in people with a known serious hypersensitivity to tirzepatide or an excipient [1]. The label states that routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection [1].
The most common adverse reactions in the label are gastrointestinal. In the pooled weight-reduction trials, nausea occurred in 25%, 29% and 28% of patients on 5, 10 and 15 mg respectively versus 8% on placebo, and 56% of tirzepatide-treated patients had any gastrointestinal adverse reaction versus 30% on placebo [1]. Severe gastrointestinal reactions occurred in 1.7%, 2.5% and 3.1% versus 1%, and the label says similar rates were seen in the OSA trials [1]. The drug is not recommended in people with severe gastroparesis [1].
Other label warnings include acute pancreatitis, with an exposure-adjusted rate of 0.84 cases per 100 patient-years in the pooled OSA trials versus 0 in placebo-treated patients, and instructions to discontinue if pancreatitis is suspected; acute gallbladder disease, with cholelithiasis in 1.1% versus 1% and cholecystitis in 0.7% versus 0.2% in the weight-reduction pool and similar cholelithiasis rates in the OSA trials; acute kidney injury from volume depletion; hypoglycemia, which is more likely with insulin or a sulfonylurea; and pulmonary aspiration during general anesthesia or deep sedation, for which the label says to inform healthcare providers of planned surgeries or procedures [1].
The label advises people using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation [1]. It says weight loss offers no benefit in pregnancy and may cause fetal harm, and that Zepbound should be discontinued when pregnancy is recognized [1].
What happens to weight if tirzepatide is stopped
Weight regain after stopping is documented. In SURMOUNT-4, 670 adults who had lost a mean 20.9% of body weight during 36 weeks of open-label tirzepatide were randomized to continue the drug or switch to placebo; from week 36 to week 88, weight changed by -5.5% with continued tirzepatide and +14.0% with placebo, a difference of 19.4 percentage points [8]. SURMOUNT-4 enrolled adults with obesity or overweight without diabetes and was not an OSA trial, and its primary outcome was weight [8]. What happens to sleep apnea severity after stopping is therefore not answered by it.
How it compares with semaglutide and bariatric surgery
In SURMOUNT-5, an open-label trial of 751 adults with obesity but no type 2 diabetes, weight changed by -20.2% with maximum tolerated tirzepatide and -13.7% with maximum tolerated semaglutide at 72 weeks [9]. That is a weight comparison, not an AHI comparison.
For bariatric surgery, a systematic review of 69 studies covering 13,900 patients found that more than 75% of patients had at least an improvement in their sleep apnea after surgery, across gastric bypass, sleeve gastrectomy, biliopancreatic diversion and adjustable gastric banding [10].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is Zepbound approved for sleep apnea?
How much does Zepbound lower AHI?
What dose was used in the sleep apnea trials?
Can Zepbound replace a CPAP machine?
Will sleep apnea return if Zepbound is stopped?
Reader questions
What people actually ask
Short answers drawn from the sources this article cites.
What kind of sleep apnea qualifies for Zepbound?
Zepbound is approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. The OSA indication is limited to adults with obesity, and it is used with a reduced-calorie diet and more physical activity.
Can Zepbound reverse sleep apnea?
The evidence here does not show that Zepbound reverses sleep apnea. In two 52-week trials, tirzepatide lowered the apnea-hypopnea index (AHI) by -25.3 and -29.3 events per hour, versus -5.3 and -5.5 with placebo, but those trials did not test whether it can replace PAP.
Does Zepbound really help with sleep apnea?
In two 52-week phase 3 trials, it lowered AHI more than placebo: -25.3 versus -5.3 events per hour in people not using PAP, and -29.3 versus -5.5 in people using PAP at baseline. Whether it lowers cardiovascular events in OSA is not established by these trials.
References
Show all 12 referencesHide references
- U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
- Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13):1193-1205.
- Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687-698.
- Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA. 2000;284(23):3015-21.
- Kanu C, Shinde S, Chakladar S, Dennehy EB, Weaver TE, Poon JL, et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity. Sleep Med. 2025;134:106719.
- McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. N Engl J Med. 2016;375(10):919-31.
- Henney AE, Riley DR, Anson M, Heague M, Hernadez G, Alam U, et al. Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence. Ann Am Thorac Soc. 2025;22(7):1042-1052.
- Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48.
- Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36.
- Sarkhosh K, Switzer NJ, El-Hadi M, Birch DW, Shi X, Karmali S. The impact of bariatric surgery on obstructive sleep apnea: a systematic review. Obes Surg. 2013;23(3):414-23.
- Reddit participants. Anyone successfully "cure" sleep apnea with Zepbound? (r/Zepbound). Accessed 2026-11-10.
- Reddit participants. Zepbound and sleep apnea (r/antidietglp1). Accessed 2026-11-10.